CPS1 and metabolic dysfunction-associated steatohepatitis: Further, OTC1 was found to be increased in NASH-fibrosis versus healthy controls (0.31 fold, FDR: 0.004) (Supplementary Fig. 1B) Further, in the second subset of patients, CPS1 expression by RNA-seq was found to be diminished in NASH patients without fibrosis when compared to bland steatosis (0.44 fold; FDR: 0.0005) and healthy controls (0.44 fold; FDR: 0.0003) (Supplementary Fig. 1C).